Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?
| Autor: | Marius Raica, Valeria Tarlui, A. Cumpanas, Sorin Bolintineanu, Alin Adrian Cumpanas, Anca Maria Cimpean |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Cancer Research Pathology medicine.medical_specialty Receptor ErbB-2 Concordance In situ hybridization Adenocarcinoma Diagnosis Differential Immunoenzyme Techniques 03 medical and health sciences Therapeutic approach 0302 clinical medicine Gene duplication Carcinoma medicine Biomarkers Tumor Humans Neoplasm Invasiveness skin and connective tissue diseases neoplasms In Situ Hybridization Fluorescence Bladder cancer business.industry Gene Amplification Fish analysis General Medicine medicine.disease 030104 developmental biology Oncology Urinary Bladder Neoplasms 030220 oncology & carcinogenesis Carcinoma Squamous Cell Immunohistochemistry business |
| Zdroj: | Anticancer research. 37(9) |
| ISSN: | 1791-7530 |
| Popis: | Background/aim To assess the concordance between IHC and FISH and its influence on tumor type, grade and lympho-vascular invasion (LVI). Materials and methods HER2 immunohistochemistry (IHC) to 45 cases of bladder carcinoma, followed by fluorescent in situ hybridization (FISH) were applied. Results 31.12% cases were IHC positive. Less than 35% of HER2-negative cases presented LVI and this percent increased to 54.54% for +1 HER2 cases. LVI increases up to 57.14% for +2 HER2 cases and slightly decreased for +3 HER2 cases to 42.85%. IHC/FISH concordance was found for 73.34% cases but 31.57% were previously negative and 36.36% scored as +1 by IHC had gene amplification as shown by FISH analysis. T3 was correlated with HER2-IHC (p=0.05) and HER2-FISH (p=0.01). Conclusion Improved HER2 assessement is needed for urothelial carcinomas. HER2-IHC scored as 0-2 should be validated by and reclassified according to FISH analysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|